The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.
Eli Lilly just struck a major deal with the world's largest retailer. GLP-1 drugs may have uses beyond obesity and diabetes ...
In results published on November 5, the Danish pharmaceutical group said it now expects sales growth of 8–11 per cent at ...
Investor's Business Daily on MSN
Novo Nordisk CFO On Metsera, Hims And Lilly, And Why 'Hyper Growth' Has Stalled
Novo Nordisk stock reversed higher Wednesday, though the Wegovy and Ozempic maker cut its sales outlook for the third time ...
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback